Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1Classical hematology 1

Conditions

Anemia 3Neoplasms 2Lymphoma, Follicular 2Anemia, Iron-Deficiency 2Plexosarcoma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Gastrointestinal Stromal Tumors 1Crohn Disease 1Colitis, Ulcerative 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 135Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 67fludarabine phosphate 61Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Cisplatin 36CTLA-4 Antigen 36Carboplatin 35cobimetinib 34Specimen Handling 34Magnetic Resonance Spectroscopy 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Iron-Dextran Complex × Clear all
NCT06508827 2025-07-09

Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma

Indiana University

Phase 2 Withdrawn
Classical hematologyDermatologic

Anemia, Melanoma, Anemia, Iron-Deficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡